---
schema_version: "secwatch.filing_event.v1"
accession: "0000899923-22-000123"
form_type: "8-K"
ticker: "MYGN"
cik: "0000899923"
company_name: "MYRIAD GENETICS INC"
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:43:01.941200+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Myriad Genetics Q2 revenue $179.3M (+7% ex-divestitures); GAAP EPS -$0.18; cuts FY EPS guidance

## Summary
- GAAP diluted EPS of $(0.18); adjusted EPS $0.04, down from $0.12 YoY.
- GeneSight volumes up 39% YoY; hereditary cancer volumes down 4% YoY but stabilizing.
- FY2022 revenue guidance unchanged at $670-$700M; adjusted EPS cut to $(0.10)-$0.00 from $0.00-$0.20.
- Cash $283.6M; paid $48M qui tam settlement in Q2; no debt.
- Launched Precise Oncology Solutions; liquid biopsy test via Illumina/Intermountain expected in 2023.

## SEC filing metadata
- accession: 0000899923-22-000123
- form_type: 8-K
- ticker: MYGN
- cik: 0000899923
- company_name: MYRIAD GENETICS INC
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/0000899923-22-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899923/000089992322000123/mygn-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000899923-22-000123
- JSON: https://secwatch.observer/filing/0000899923-22-000123.json
- Plain text: https://secwatch.observer/filing/0000899923-22-000123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.